Clinical Trial

Testing Experimental Medication in Healthy Subjects

Study Description

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

This is a Phase 1, open-label, randomized, parallel design study to evaluate the PK and safety/tolerability of CC 90001 in Japanese and Caucasian healthy adult subjects. The study will consist of multiple oral doses of IP (QD x 7 days) in 3 planned dose level cohorts of 100 mg, 200 mg, and 400 mg. Each cohort will have 20 subjects (10 Japanese subjects and 10 Caucasian subjects, with a minimum of 8 subjects to complete in each group) who will receive IP (see below).

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - CC-90001

CC-90001

Additional Information

Official Study Title

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics and Safety/Tolerability of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

Clinical Trial ID

NCT03958864

ParticipAid ID

bo2lYa